The Utility of BSND Immunohistochemistry in the Differential Diagnosis of Oncocytic and Warthin-like Mucoepidermoid Carcinoma of Salivary Gland

Overview

Journal Head Neck Pathol

Specialties Oncology
Pathology

Date 2024 Nov 26

PMID 39589616

Authors

Bin Xu

Achim Jungbluth

Denise Frosina

Anas Alabkaa

Rene Serrette

Howard Qin

Dibisha Roy

Ronald Ghossein

Nora Katabi

Affiliations

Soon will be listed here.

Abstract

Purpose: BSND is a chloride channel subunit that is expressed in the normal salivary gland. We aimed to validate the utility of BSND immunohistochemistry in the differential diagnosis of oncocytic salivary gland neoplasms.

Methods: BSND immunohistochemistry was performed in a retrospective cohort of 93 salivary gland lesions, enriched with tumors with oncocytic features and histologic variants of mucoepidermoid carcinoma (MEC).

Results: All oncocytomas (n = 18) showed diffuse membranous BSND immunopositivity. Warthin tumors (n = 18) were also positive for BSND, but the staining pattern was patchy cytoplasmic and membranous in 10-25% of tumor cells. Using a threshold of 10% BSND-positive cells, all Warthin tumors were positive, while none of Warthin-like MECs or non-MEC salivary tumors were positive. Applying the same 10% positivity criterion, two oncocytic MECs were positive for BSND. The percentage of BSND staining in oncocytic MECs was up to 20%. In contrast, BSND was diffusely positive in oncocytomas with a median percentage of positivity of 95% (range: 40 - 100%). Therefore, a higher threshold of > 20% BSND-positive cells may be considered when differentiating between oncocytoma and oncocytic MEC.

Conclusion: BSND immunohistochemistry is a potentially useful diagnostic marker for salivary gland neoplasms, especially oncocytic and Warthin-like MECs. A threshold of ≥ 10% positivity can differentiate Warthin tumors from Warthin-like MECs, whereas > 20% positivity can be effective for separating oncocytomas from oncocytic MECs.

References

Shinmura K, Igarashi H, Kato H, Koda K, Ogawa H, Takahashi S . BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma. Medicine (Baltimore). 2015; 94(24):e989. PMC: 4616546. DOI: 10.1097/MD.0000000000000989. View

Katabi N . Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry. Head Neck Pathol. 2024; 18(1):20. PMC: 10951193. DOI: 10.1007/s12105-024-01622-9. View

Brennan T, Landau D, Shalev H, Lamb F, Schutte B, Walder R . Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p. Am J Hum Genet. 1998; 62(2):355-61. PMC: 1376884. DOI: 10.1086/301708. View

Birkenhager R, Otto E, Schurmann M, Vollmer M, Ruf E, Beekmann F . Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001; 29(3):310-4. DOI: 10.1038/ng752. View

Rooper L, Agaimy A, Assaad A, Bal M, Eugene H, Gagan J . Recurrent IDH2 Mutations in Salivary Gland Striated Duct Adenoma Define an Expanded Histologic Spectrum Distinct From Canalicular Adenoma. Am J Surg Pathol. 2022; 47(3):333-343. DOI: 10.1097/PAS.0000000000002004. View

Heatley N, Harrington K, Thway K . Warthin Tumor-Like Mucoepidermoid Carcinoma. Int J Surg Pathol. 2017; 26(1):31-33. DOI: 10.1177/1066896917724889. View

Seethala R . Oncocytic and apocrine epithelial myoepithelial carcinoma: novel variants of a challenging tumor. Head Neck Pathol. 2013; 7 Suppl 1:S77-84. PMC: 3712087. DOI: 10.1007/s12105-013-0461-0. View

Seethala R, Richmond J, Hoschar A, Barnes E . New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine. Arch Pathol Lab Med. 2009; 133(6):950-9. DOI: 10.5858/133.6.950. View

Katabi N, Sukhadia P, DiNapoli S, Weinreb I, Hahn E, Ghossein R . Expanding the histological spectrum of salivary gland neoplasms with HMGA2::WIF1 fusion emphasising their malignant potential: a report of eight cases. Histopathology. 2023; 84(2):387-398. PMC: 10841865. DOI: 10.1111/his.15074. View

10.

Shinmura K, Kato H, Kawanishi Y, Kamo T, Inoue Y, Yoshimura K . BSND is a Novel Immunohistochemical Marker for Oncocytic Salivary Gland Tumors. Pathol Oncol Res. 2017; 24(2):439-444. DOI: 10.1007/s12253-017-0248-9. View

11.

Weinreb I, Seethala R, Perez-Ordonez B, Chetty R, Hoschar A, Hunt J . Oncocytic mucoepidermoid carcinoma: clinicopathologic description in a series of 12 cases. Am J Surg Pathol. 2008; 33(3):409-16. DOI: 10.1097/PAS.0b013e318184b36d. View

12.

Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K . Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2018; 32(5):609-620. PMC: 6486453. DOI: 10.1038/s41379-018-0175-7. View